Recent Advances in Anti-Angiogenic Therapy of Cancer

Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs...

Descripción completa

Detalles Bibliográficos
Autores principales: Samant, Rajeev S., Shevde, Lalita A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2011
Materias:
Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260813/
https://www.ncbi.nlm.nih.gov/pubmed/21399234
_version_ 1782221528643928064
author Samant, Rajeev S.
Shevde, Lalita A.
author_facet Samant, Rajeev S.
Shevde, Lalita A.
author_sort Samant, Rajeev S.
collection PubMed
description Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents.
format Online
Article
Text
id pubmed-3260813
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-32608132012-01-18 Recent Advances in Anti-Angiogenic Therapy of Cancer Samant, Rajeev S. Shevde, Lalita A. Oncotarget Reviews Since angiogenesis is critical for tumor growth and metastasis, anti-angiogenic treatment is a highly promising therapeutic approach. Thus, for over last couple of decades, there has been a robust activity aimed towards the discovery of angiogenesis inhibitors. More than forty anti-angiogenic drugs are being tested in clinical trials all over the world. This review discusses agents that have approved by the FDA and are currently in use for treating patients either as single-agents or in combination with other chemotherapeutic agents. Impact Journals LLC 2011-03-07 /pmc/articles/PMC3260813/ /pubmed/21399234 Text en Copyright: © 2011 Samant and Shevde http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
spellingShingle Reviews
Samant, Rajeev S.
Shevde, Lalita A.
Recent Advances in Anti-Angiogenic Therapy of Cancer
title Recent Advances in Anti-Angiogenic Therapy of Cancer
title_full Recent Advances in Anti-Angiogenic Therapy of Cancer
title_fullStr Recent Advances in Anti-Angiogenic Therapy of Cancer
title_full_unstemmed Recent Advances in Anti-Angiogenic Therapy of Cancer
title_short Recent Advances in Anti-Angiogenic Therapy of Cancer
title_sort recent advances in anti-angiogenic therapy of cancer
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3260813/
https://www.ncbi.nlm.nih.gov/pubmed/21399234
work_keys_str_mv AT samantrajeevs recentadvancesinantiangiogenictherapyofcancer
AT shevdelalitaa recentadvancesinantiangiogenictherapyofcancer

Ejemplares similares